Equities

Kymera Therapeutics Inc

KYMR:NMQ

Kymera Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)49.03
  • Today's Change2.59 / 5.58%
  • Shares traded484.56k
  • 1 Year change+161.49%
  • Beta2.2273
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy6
Outperform7
Hold4
Sell0
Strong Sell0

Share price forecast in USD

The 15 analysts offering 12 month price targets for Kymera Therapeutics Inc have a median target of 52.00, with a high estimate of 106.00 and a low estimate of 36.00. The median estimate represents a 6.06% increase from the last price of 49.03.
High116.2%106.00
Med6.1%52.00
Low-26.6%36.00

Earnings history & estimates in USD

On Aug 07, 2024, Kymera Therapeutics Inc reported 2nd quarter 2024 losses of -0.58 per share. This result exceeded the -0.68 consensus loss of the 15 analysts covering the company and exceeded last year's 2nd quarter results by 13.43%.
The next earnings announcement is expected on Oct 31, 2024.
Average growth rate-30.54%
Kymera Therapeutics Inc reported annual 2023 losses of -2.52 per share on Feb 22, 2024.
Average growth rate+2.84%
More ▼

Revenue history & estimates in USD

Kymera Therapeutics Inc had 2nd quarter 2024 revenues of 25.65m. This bettered the 12.55m consensus of the 16 analysts covering the company. This was 170.97% above the prior year's 2nd quarter results.
Average growth rate+228.06%
Kymera Therapeutics Inc had revenues for the full year 2023 of 78.59m. This was 67.84% above the prior year's results.
Average growth rate+48.71%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.